The new bis-platinum based compounds, contains two platinum atoms and work by binding to and damaging both strands of DNA making it much more difficult for cancer cells to repair the damage. This new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrates a stronger anti-tumor potency and activity compared to presently available platinum-based compounds as well as the ability to defeat cisplatin-resistance in cancer cell lines.
Research demonstrated through cancer cell assays and animal tumor models that the bis-platinum complexes revealed greater cytotoxic potency and anti-tumor outcome compared to cisplatin and oxaliplatin. A 200-fold increase in percent accumulation in tumor cells of the bisplatinum compounds compared to cisplatin and oxaliplatin was apparent.
“Platinum-based compounds are cornerstone agents in the treatment of very common cancers such as cancers of the lung, colon, and ovary and are also widely used in other gynecological tumors, testicular cancers, and cancers of the esophagus, head and neck. They are increasingly being used for salvage therapy in lymphoma. However, resistance to palatinate compounds is common. The current results are encouraging as they demonstrate that the bisplatinates are not only more effective in human tumor models than the current agents, but also capable of overcoming some forms of palatinate resistance," said Jack Singer, M.D., Chief Medical Officer of CTI.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
About Cell Therapeutics, Inc.
Headquartered in
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
